Which of the following is an absolute contraindication to OCP use?

Explanation

## Correct Answer: B. Thromboembolism Thromboembolism (both venous and arterial) is an **absolute contraindication** to OCP use because OCPs increase the risk of thrombosis through multiple mechanisms: increased hepatic synthesis of clotting factors (II, VII, IX, X), increased platelet aggregability, and reduced fibrinolysis. A woman with a personal history of deep vein thrombosis (DVT), pulmonary embolism (PE), or arterial thrombosis (stroke, MI) has already demonstrated a prothrombotic tendency and faces unacceptable risk of recurrence if exposed to the additional thrombogenic stimulus of estrogen-progestin combinations. This is classified as **Category 4** (absolute contraindication) by WHO Medical Eligibility Criteria. The risk is particularly high with combined OCPs containing ethinyl estradiol; even progestin-only pills carry some risk in thrombotic disease. Indian guidelines (FOGSI, ICOG) and standard practice in Indian tertiary centers strictly avoid OCPs in such patients, offering alternatives like copper-T, progestin-only pills, or barrier methods instead. ## Why the other options are wrong **A. Chronic renal disease** — Chronic renal disease is a **relative contraindication** (WHO Category 3), not absolute. OCPs can be used with caution in mild-to-moderate CKD if blood pressure is controlled and proteinuria is absent. The concern is worsening hypertension and renal function, not an insurmountable barrier. Many Indian nephrologists permit OCPs in stable CKD Stage 1–2 patients. **C. History of amenorrhea** — Amenorrhea is **not a contraindication**; it may even be an indication for OCPs in secondary amenorrhea due to anovulation or PCOS. OCPs restore regular cycles and reduce endometrial hyperplasia risk. This is a common therapeutic use in Indian gynecology practice, not a warning sign against their use. **D. Diabetes mellitus** — Diabetes is a **relative contraindication** (WHO Category 2–3 depending on duration, complications, and vascular disease). Uncomplicated Type 2 DM or well-controlled Type 1 DM without microvascular/macrovascular complications allows OCP use with monitoring. Only if diabetes is complicated by nephropathy, retinopathy, or vascular disease does it become Category 3–4. This is not an absolute bar. ## High-Yield Facts - **Absolute contraindications to OCPs (WHO Category 4)**: history of VTE/PE, current/past stroke or MI, major surgery with immobilization, thrombophilia (Factor V Leiden, prothrombin mutation), migraine with aura, uncontrolled hypertension (≥160/100 mmHg), and smoking >15 cigarettes/day after age 35. - **Estrogen-induced thrombosis mechanism**: increased synthesis of procoagulants (factors II, VII, IX, X), decreased protein S and antithrombin, increased platelet reactivity, and reduced fibrinolysis—all reversible within weeks of OCP cessation. - **WHO Medical Eligibility Criteria Category 4** means the contraindication is absolute; risks clearly outweigh benefits and the method should not be used. - **Progestin-only pills (POP)** carry lower thrombotic risk than combined OCPs and may be considered in some thrombotic conditions, but are still relatively contraindicated in active VTE. - **Indian clinical pearl**: In a woman presenting with DVT/PE, always ask about OCP use; if present, discontinue immediately and switch to copper-T or barrier methods; counsel on warning signs (leg swelling, chest pain, dyspnea). ## Mnemonics **ACHES mnemonic for OCP danger signs** **A**bdominal pain (severe), **C**hest pain, **H**eadache (severe/migraine with aura), **E**ye problems (vision loss), **S**evere leg pain/swelling (DVT/PE). If any ACHES symptom develops, stop OCP immediately and seek medical care. **Absolute OCP contraindications: VTE-SHAG** **V**TE/PE history, **T**hrombophilia, **E**strogen-sensitive cancer, **S**evere migraine with aura, **H**ypertension uncontrolled, **A**ge >35 + smoking, **G**allbladder disease (relative). This memory hook groups the most critical absolute barriers. ## NBE Trap NBE may pair thromboembolism with "relative contraindication" language or offer it alongside relative contraindications (diabetes, renal disease) to test whether students confuse WHO Category 3 (relative) with Category 4 (absolute). The trap is conflating "increased risk" with "absolute contraindication"—diabetes increases risk but doesn't absolutely forbid OCPs, whereas thromboembolism history does. ## Clinical Pearl In Indian outpatient gynecology, a 28-year-old woman with a recent DVT post-surgery presents requesting OCPs for cycle regulation. The absolute contraindication is her thrombotic history, not the indication. Counsel her on copper-T insertion or progestin-only pills, and ensure thrombophilia screening (Factor V Leiden, prothrombin G20210A) is done before discharge—critical in Indian tertiary centers where genetic thrombophilia prevalence is rising. _Reference: DC Dutta's Textbook of Obstetrics (8th ed.) Ch. 27 (Contraception); WHO Medical Eligibility Criteria for Contraceptive Use (5th ed., 2015); FOGSI Guidelines on Contraception_